Stay updated on BA3071 in PD-1 Combo for Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the BA3071 in PD-1 Combo for Solid Tumors Clinical Trial page.
Latest updates to the BA3071 in PD-1 Combo for Solid Tumors Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check23 days agoChange DetectedA new Phase 1/2 study of BA3071 in patients with solid tumors has been added, focusing on a combination therapy with chemotherapy, while a previous study involving BA3071 as monotherapy and in combination with a PD-1 blocking antibody has been removed.SummaryDifference8%
- Check44 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check65 days agoChange DetectedA new Phase 1/2 study of BA3071 is now enrolling patients with nonsquamous or recurrent NSCLC and melanoma, focusing on specific genetic mutations, while a previous study involving advanced solid tumors has been removed.SummaryDifference22%
- Check72 days agoChange DetectedDifference0.4%
- Check79 days agoChange DetectedDifference1%
Stay in the know with updates to BA3071 in PD-1 Combo for Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BA3071 in PD-1 Combo for Solid Tumors Clinical Trial page.